Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20665012 | 0.90 | KMT2A (0.54) | KMT2AEPHX2TLR2TLR1OPRD1 | |
| SCHEMBL20665020 | 0.85 | KMT2A (0.56) | KMT2AEPHX2OPRD1CASP3 | |
| SCHEMBL1007491 | 0.85 | KMT2A (0.58) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL7876414 | 0.84 | KMT2A (0.57) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL469368 | 0.83 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL30095461 | 0.83 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL20665019 | 0.83 | KMT2A (0.54) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL20759216 | 0.83 | KMT2A (0.54) | KMT2AEPHX2TLR2TLR1OPRD1 | |
| SCHEMBL20759374 | 0.83 | KMT2A (0.54) | KMT2AEPHX2TLR2TLR1OPRD1 | |
| SCHEMBL12893658 | 0.82 | KMT2A (0.53) | KMT2AEPHX2TLR2TLR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885TLR2 1263/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885TLR2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.